vs
Side-by-side financial comparison of AvalonBay Communities (AVB) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $767.9M, roughly 1.6× AvalonBay Communities). AvalonBay Communities runs the higher net margin — 9040.6% vs 17.0%, a 9023.6% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 3.7%). AvalonBay Communities produced more free cash flow last quarter ($1.4B vs $345.8M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 3.8%).
AvalonBay Communities, Inc. is a publicly traded real estate investment trust that invests in apartments.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AVB vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $767.9M | $1.2B |
| Net Profit | $166.0M | $203.5M |
| Gross Margin | — | — |
| Operating Margin | 64.2% | 21.2% |
| Net Margin | 9040.6% | 17.0% |
| Revenue YoY | 3.7% | 10.1% |
| Net Profit YoY | -41.2% | 6.5% |
| EPS (diluted) | $1.18 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $767.9M | $1.2B | ||
| Q3 25 | $766.8M | $1.1B | ||
| Q2 25 | $760.2M | $1.0B | ||
| Q1 25 | $745.9M | $897.8M | ||
| Q4 24 | $740.5M | $1.1B | ||
| Q3 24 | $734.3M | $1.1B | ||
| Q2 24 | $726.0M | $1.0B | ||
| Q1 24 | $712.9M | $902.0M |
| Q4 25 | $166.0M | $203.5M | ||
| Q3 25 | $381.3M | $251.4M | ||
| Q2 25 | $268.7M | $-718.5M | ||
| Q1 25 | $236.6M | $-92.5M | ||
| Q4 24 | $282.1M | $191.1M | ||
| Q3 24 | $372.5M | $215.1M | ||
| Q2 24 | $253.9M | $168.6M | ||
| Q1 24 | $173.4M | $-14.6M |
| Q4 25 | 64.2% | 21.2% | ||
| Q3 25 | 65.7% | 5.1% | ||
| Q2 25 | 67.6% | -65.6% | ||
| Q1 25 | 68.5% | -6.2% | ||
| Q4 24 | 63.1% | 17.5% | ||
| Q3 24 | 65.4% | 24.7% | ||
| Q2 24 | 66.6% | 19.5% | ||
| Q1 24 | 67.2% | 7.3% |
| Q4 25 | 9040.6% | 17.0% | ||
| Q3 25 | 49.7% | 22.3% | ||
| Q2 25 | 35.3% | -68.7% | ||
| Q1 25 | 31.7% | -10.3% | ||
| Q4 24 | 38.1% | 17.6% | ||
| Q3 24 | 50.7% | 20.4% | ||
| Q2 24 | 35.0% | 16.5% | ||
| Q1 24 | 24.3% | -1.6% |
| Q4 25 | $1.18 | $3.34 | ||
| Q3 25 | $2.68 | $4.08 | ||
| Q2 25 | $1.88 | $-11.74 | ||
| Q1 25 | $1.66 | $-1.52 | ||
| Q4 24 | $1.99 | $2.97 | ||
| Q3 24 | $2.61 | $3.42 | ||
| Q2 24 | $1.78 | $2.49 | ||
| Q1 24 | $1.22 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $187.2M | $1.4B |
| Total DebtLower is stronger | $9.3B | $5.4B |
| Stockholders' EquityBook value | $11.6B | $4.3B |
| Total Assets | $22.2B | $11.7B |
| Debt / EquityLower = less leverage | 0.80× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $187.2M | $1.4B | ||
| Q3 25 | $123.3M | $1.3B | ||
| Q2 25 | $102.8M | $1.2B | ||
| Q1 25 | $53.3M | $1.9B | ||
| Q4 24 | $108.6M | $2.4B | ||
| Q3 24 | $552.4M | $2.2B | ||
| Q2 24 | $545.8M | $1.4B | ||
| Q1 24 | $287.9M | $1.4B |
| Q4 25 | $9.3B | $5.4B | ||
| Q3 25 | $8.7B | $5.4B | ||
| Q2 25 | $8.7B | $5.4B | ||
| Q1 25 | $8.3B | $5.4B | ||
| Q4 24 | $8.1B | $6.1B | ||
| Q3 24 | $8.4B | $6.1B | ||
| Q2 24 | $8.4B | $5.7B | ||
| Q1 24 | $8.0B | $5.7B |
| Q4 25 | $11.6B | $4.3B | ||
| Q3 25 | $11.9B | $4.0B | ||
| Q2 25 | $11.9B | $3.7B | ||
| Q1 25 | $11.9B | $4.2B | ||
| Q4 24 | $11.9B | $4.1B | ||
| Q3 24 | $11.9B | $4.2B | ||
| Q2 24 | $11.7B | $3.8B | ||
| Q1 24 | $11.7B | $3.7B |
| Q4 25 | $22.2B | $11.7B | ||
| Q3 25 | $21.9B | $11.4B | ||
| Q2 25 | $21.8B | $10.9B | ||
| Q1 25 | $21.2B | $11.5B | ||
| Q4 24 | $21.0B | $12.0B | ||
| Q3 24 | $21.3B | $12.3B | ||
| Q2 24 | $21.0B | $11.4B | ||
| Q1 24 | $20.6B | $11.3B |
| Q4 25 | 0.80× | 1.24× | ||
| Q3 25 | 0.73× | 1.35× | ||
| Q2 25 | 0.72× | 1.45× | ||
| Q1 25 | 0.70× | 1.29× | ||
| Q4 24 | 0.68× | 1.49× | ||
| Q3 24 | 0.70× | 1.47× | ||
| Q2 24 | 0.71× | 1.52× | ||
| Q1 24 | 0.68× | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7B | $362.5M |
| Free Cash FlowOCF − Capex | $1.4B | $345.8M |
| FCF MarginFCF / Revenue | 183.5% | 28.9% |
| Capex IntensityCapex / Revenue | 34.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 10.07× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $2.5B | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $362.5M | ||
| Q3 25 | $477.0M | $474.6M | ||
| Q2 25 | $377.8M | $88.9M | ||
| Q1 25 | $415.9M | $429.8M | ||
| Q4 24 | $1.6B | $398.6M | ||
| Q3 24 | $486.2M | $398.7M | ||
| Q2 24 | $380.0M | $331.4M | ||
| Q1 24 | $412.9M | $267.2M |
| Q4 25 | $1.4B | $345.8M | ||
| Q3 25 | $402.2M | $459.4M | ||
| Q2 25 | $317.1M | $75.9M | ||
| Q1 25 | $367.5M | $415.9M | ||
| Q4 24 | $1.4B | $385.3M | ||
| Q3 24 | $434.2M | $388.0M | ||
| Q2 24 | $333.0M | $324.3M | ||
| Q1 24 | $375.4M | $260.3M |
| Q4 25 | 183.5% | 28.9% | ||
| Q3 25 | 52.5% | 40.8% | ||
| Q2 25 | 41.7% | 7.3% | ||
| Q1 25 | 49.3% | 46.3% | ||
| Q4 24 | 191.0% | 35.4% | ||
| Q3 24 | 59.1% | 36.8% | ||
| Q2 24 | 45.9% | 31.7% | ||
| Q1 24 | 52.7% | 28.9% |
| Q4 25 | 34.1% | 1.4% | ||
| Q3 25 | 9.8% | 1.3% | ||
| Q2 25 | 8.0% | 1.2% | ||
| Q1 25 | 6.5% | 1.5% | ||
| Q4 24 | 26.1% | 1.2% | ||
| Q3 24 | 7.1% | 1.0% | ||
| Q2 24 | 6.5% | 0.7% | ||
| Q1 24 | 5.3% | 0.8% |
| Q4 25 | 10.07× | 1.78× | ||
| Q3 25 | 1.25× | 1.89× | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | 5.70× | 2.09× | ||
| Q3 24 | 1.31× | 1.85× | ||
| Q2 24 | 1.50× | 1.97× | ||
| Q1 24 | 2.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVB
Segment breakdown not available.
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
